Figure 1.

Protocols for identifying and transferring tumor-reactive T cells. (A) A “blueprint” for the therapy of patients using autologous T cells that recognize tumor-specific mutations. TILs, tumor-infiltrating lymphocytes; APCs, antigen-presenting cells; MHC, major histocompatibility complex; TCR, T cell receptor; PBMC, peripheral blood mononuclear cell. (B) A “blueprint” for the therapy of patients with autologous T cells recognizing tumor cells that were sorted by chronic activation markers such as CD39.